How to get tesamorelin: the legal, provider-reviewed route

Last updated 2026-07-24

What exactly is tesamorelin, and why do you need a prescription for it?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on the pituitary and stimulates the body's own pulsatile release of growth hormone, which in turn raises IGF-1. That mechanism is well characterized in the pharmacology literature going back to its original development program ^[1][2]. It is not a growth hormone itself. It is upstream of GH, which is part of why the safety profile in trials looks different from injecting GH directly. The FDA approved it under the brand name Egrifta (and later Egrifta SV, a reformulated version) specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy ^[3][4]. Because it acts on a hormonal axis and carries a labeled indication with real contraindications, it is a prescription drug in the United States, not a supplement, and not something you can legally buy without a licensed provider's order. Any site selling it as a "research chemical" for personal use is operating outside the drug's approved supply chain. That doesn't automatically mean the peptide inside the vial is fake, but it does mean nobody has verified purity, sterility, or dose accuracy, and there's no medical oversight if something goes wrong.

What is tesamorelin actually FDA-approved for?

The approved indication is narrow: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That's it. It is not approved for general fat loss, bodybuilding, anti-aging use, or GH support in people without HIV-associated lipodystrophy. The core evidence base is two multicenter, double-blind, placebo-controlled phase 3 trials pooled with safety extension data, published in the Journal of Clinical Endocrinology and Metabolism ^[4]. Follow-on work has since shown that visceral fat reduction with tesamorelin correlates with improved liver enzymes in this population ^[5], and a randomized double-blind multicenter trial found effects on non-alcoholic fatty liver disease (NAFLD) markers in people with HIV ^[6]. A 2021 study also found tesamorelin improves fat quality (reducing fat density/attenuation on imaging) independent of the raw amount of fat lost ^[7], and post hoc analysis has examined whether patients with or without dorsocervical fat pads ("buffalo hump") respond differently ^[8]. More recent randomized work has extended into related questions: a 2024 study in AIDS looked at efficacy and safety of tesamorelin in people with HIV specifically on integrase inhibitor regimens ^[9], and a 2025 trial in the Journal of Infectious Diseases examined effects on neurocognitive impairment in people with HIV and abdominal obesity ^[10]. None of this expands the FDA label. It expands what researchers know about the drug in the population it was actually studied in.

Can you get tesamorelin without HIV-associated lipodystrophy?

Yes, but it's off-label, and you should go in with clear eyes about what that means. Off-label prescribing is legal in the US: a licensed physician, nurse practitioner, or PA can prescribe an FDA-approved drug for a use outside its label if they judge it appropriate for the patient in front of them. What off-label use does NOT mean is that the phase 3 evidence transfers. The trials that support the approval ^[4][6] enrolled people with HIV-associated lipodystrophy, a specific medical condition with its own diagnostic criteria ^[11][12]. If you're a 45-year-old without HIV asking about tesamorelin for visceral fat or general GH support, there is no equivalent phase 3 dataset for you. A 2026 review of therapeutic peptides in orthopaedic and sports medicine contexts explicitly frames tesamorelin and similar GHRH analogues as requiring more caution and evidence outside their approved populations ^[13][14]. Some prescribers, often in telehealth or longevity-focused practices, will still write for it off-label based on the mechanism (raising endogenous GH/IGF-1) and the approved drug's safety record. That's a legitimate clinical judgment call for a licensed doctor to make, and plenty do. Just don't let anyone tell you it's "basically FDA approved for this too." It isn't. See our main tesamorelin overview for the full evidence rundown before you have that conversation with a prescriber.

What's the actual step-by-step process to get a prescription?

1. Get evaluated by a licensed prescriber. This can be an infectious disease specialist or endocrinologist (for the on-label indication), your regular physician, or a telehealth prescriber willing to consider off-label use. Expect bloodwork: IGF-1 baseline, glucose/HbA1c (tesamorelin can raise blood glucose), and a review of your medical history. 2. Get the diagnosis or clinical rationale documented. On-label, this means confirmed HIV status plus a lipodystrophy assessment. Off-label, your prescriber documents why they think it's reasonable for you specifically. 3. Get the prescription filled. You have two real paths here: the branded product (Egrifta SV) through a specialty pharmacy, usually if you're going through the on-label HIV lipodystrophy indication and possibly using manufacturer support programs; or a compounded version through a state-licensed compounding pharmacy, which is far more common for off-label use since compounders can dispense in more flexible formats and at different price points. 4. Get instructed on reconstitution and injection. Whichever route you take, you need real training on mixing bacteriostatic water with the lyophilized powder and drawing correct doses. Our tesamorelin reconstitution guide covers the mechanics, but your pharmacy or provider should walk you through it too. 5. Get monitored. Follow-up bloodwork (IGF-1, glucose) is standard practice given the drug's mechanism and the class effects documented in growth hormone literature on aging populations ^[15].

Branded Egrifta vs. compounded tesamorelin: what's the difference?

Both contain the same peptide sequence, tesamorelin acetate. The differences are regulatory status, formulation, and price. | Factor | Branded (Egrifta SV) | Compounded |

How much does it cost to get tesamorelin, and does insurance cover it?

Insurance coverage for the branded product typically only applies when you meet the on-label criteria: documented HIV-associated lipodystrophy. Even then, prior authorization is common, and many insurers still push back given the drug's specialty pricing. If you're pursuing tesamorelin off-label, expect to pay out of pocket. Compounded versions from licensed pharmacies are generally the more affordable route, though price varies a lot by pharmacy, dose, and region. We break down real dollar ranges in tesamorelin cost. The short version: don't be shocked if a monthly supply runs into the hundreds of dollars regardless of which route you choose. Anyone quoting prices that look too good to be true for a real pharmaceutical peptide is a signal to ask harder questions about where the product actually comes from.

What dose will a doctor prescribe, and how is it administered?

The FDA-approved dosing for Egrifta/Egrifta SV is a daily subcutaneous injection, with the exact volume depending on formulation and reconstitution. Population pharmacokinetic modeling in HIV-infected patients and healthy subjects has characterized how absorption and clearance behave across this daily dosing schedule ^[22], which is part of why the label settled on a once-daily regimen rather than less frequent dosing. Your actual dose gets set by your prescriber based on the product used, your labs, and your response. This isn't something to self-titrate. For the specifics on injection sites, frequency, and how doses are typically measured out, see tesamorelin dosage and use the tesamorelin dosage calculator to sanity-check reconstitution math, though it doesn't replace a pharmacist's or provider's direct instruction.

What are the risks and side effects a prescriber should walk you through?

The most consistently reported issues across the trial literature are injection site reactions, joint or muscle discomfort (arthralgia/myalgia), swelling (fluid retention), and increases in blood glucose or IGF-1 above normal range. The phase 3 pooled analysis with safety extension data specifically tracked these across a longer follow-up window ^[4]. Because tesamorelin raises IGF-1, prescribers watch for signs of anything that could be aggravated by growth hormone axis activity, and the drug is generally avoided in people with active malignancy or pituitary tumors, per label contraindications. A 2011 study also looked at inflammatory markers in HIV patients with excess abdominal fat and their relationship to visceral fat reduction on tesamorelin ^[23], which is useful mechanistic context but not a substitute for your own bloodwork. For the fuller list of documented adverse effects and how they're monitored, read tesamorelin peptide side effects before you start.

How do you know if a source or pharmacy is legitimate?

A few practical checks. A legitimate route always starts with a real medical evaluation, more than a form you fill out and immediately get a vial shipped. It always requires a prescription, whether that prescription comes from your regular doctor, a specialist, or a telehealth platform with licensed prescribers on staff. A legitimate compounding pharmacy is licensed in the state it operates from (and in yours, if shipping across state lines) and can answer direct questions about whether it operates as a 503A or 503B facility. It sources its bulk tesamorelin from a supplier compliant with FDA's bulk drug substance framework ^{[16][17][19][20]}, and it will not dodge questions about testing or sourcing. Red flags: no prescription required, prices that seem impossibly low, marketing language calling it a "research peptide" for human self-experimentation, or a website that never mentions a licensed pharmacy or physician by name. Tesamorelin Co's role in this picture is educational and provider-review focused; it does not compound or manufacture anything itself, and the actual dispensing happens through a licensed pharmacy partner that fulfills provider-reviewed orders.

Is tesamorelin banned in sports, or does using it flag on a drug test?

Tesamorelin, as a GHRH analogue, falls under substances of interest to anti-doping bodies because it stimulates endogenous GH release, a class WADA prohibits at all times for competitive athletes. Analytical chemistry work has specifically focused on improving detection methods for GHRH synthetic analogs, reflecting real testing capability in this space ^[24]. A broader review of injectable peptide therapy aimed at orthopaedic and sports medicine physicians flags GHRH analogues as a category clinicians should understand for exactly this reason: patients and athletes are increasingly asking about them, and misunderstanding the doping implications carries real career consequences ^[25]. If you compete under any drug-tested federation, treat tesamorelin as a banned-substance risk regardless of your reason for using it, and have that conversation with your prescriber and, if relevant, your sport's anti-doping authority before starting.

What should you ask your doctor before starting tesamorelin?

Bring a short, specific list. Ask what your baseline IGF-1 and glucose look like and how often they'll get rechecked. Ask whether you're being prescribed on-label or off-label, and have them explain their reasoning either way. Ask which product, branded or compounded, and why. Ask what specific side effects to watch for and when to call versus when to just note it and mention it at follow-up. If your reason for interest is general GH support or visceral fat reduction outside an HIV lipodystrophy diagnosis, say so plainly. A good prescriber will tell you honestly that the strongest evidence is in a different population ^[4][6] and will set expectations accordingly rather than let the FDA-approval halo imply more than it does.

Frequently asked questions

Do you need a prescription to get tesamorelin legally?

Yes. Tesamorelin is FDA-approved as a prescription drug (brand name Egrifta/Egrifta SV) for HIV-associated lipodystrophy, and it is regulated as a prescription substance in the United States. There is no legal over-the-counter or supplement version for human use. Any seller offering it without a prescription is operating outside the approved drug supply chain, with no verified purity or medical oversight.

Can a regular doctor prescribe tesamorelin, or do you need a specialist?

A licensed physician, nurse practitioner, or PA can technically prescribe tesamorelin. In practice, on-label prescribing for HIV-associated lipodystrophy often runs through infectious disease specialists or endocrinologists who diagnose lipodystrophy directly. Off-label prescribing is more commonly handled by primary care doctors, telehealth platforms, or clinics focused on hormone or metabolic health, based on their own clinical judgment.

Is it legal to get tesamorelin for weight loss instead of HIV lipodystrophy?

It's legal for a licensed prescriber to write it off-label for reasons beyond the FDA label, including general fat reduction goals, since off-label prescribing itself is legal in the US. What's missing is the phase 3 evidence: the core trials studied HIV-associated lipodystrophy specifically, not general weight loss or visceral fat in people without HIV.

What's the difference between branded Egrifta and compounded tesamorelin?

Egrifta SV is the FDA-approved finished drug product, manufactured under an approved New Drug Application. Compounded tesamorelin is made by a licensed pharmacy from bulk drug substance under 503A or 503B rules, not FDA-approved as a finished product itself. Both use the same peptide, but branded product carries FDA manufacturing oversight that compounded versions don't have in the same form.

How much does tesamorelin cost without insurance?

Cost varies widely by whether you use branded or compounded product, your dose, and your pharmacy. Insurance typically only covers the branded product for on-label HIV lipodystrophy, and even then often requires prior authorization. Off-label users paying cash usually go the compounded route, which tends to be cheaper. See a full cost breakdown in our tesamorelin cost guide.

Does tesamorelin show up on a drug test for athletes?

Tesamorelin is a GHRH analogue, a class prohibited at all times under anti-doping rules for competitive athletes, because it stimulates the body's own growth hormone release. Detection methods for GHRH synthetic analogs have been an active area of analytical chemistry research. Any competitive athlete under drug testing should assume tesamorelin carries a real doping-violation risk.

What monitoring or bloodwork do you need while on tesamorelin?

Standard practice includes baseline and follow-up IGF-1 levels and glucose or HbA1c monitoring, since tesamorelin raises IGF-1 and can affect blood glucose. Phase 3 trial data with safety extension periods tracked these markers over extended follow-up. Your prescriber should set a specific recheck schedule rather than leave monitoring open-ended.

Can you buy tesamorelin online without seeing a doctor first?

Not legitimately for human use. Any legal path to tesamorelin requires a prescription from a licensed prescriber, whether through an in-person visit or a telehealth evaluation. Sites selling it as a research chemical without medical evaluation are outside the approved drug supply chain, and purity, dosing accuracy, and safety oversight are not guaranteed in that market.

What side effects should you expect when starting tesamorelin?

The most commonly reported effects in trial data are injection site reactions, joint and muscle discomfort, fluid retention or swelling, and elevated IGF-1 or blood glucose. Most are described as manageable in the phase 3 safety extension data, but they're real and worth discussing with your prescriber before you start, along with a plan for what symptoms warrant a call versus routine follow-up.

Is compounded tesamorelin as safe as the branded version?

It depends entirely on the individual pharmacy. Compounded tesamorelin can be made under legitimate 503A or 503B rules using FDA-recognized bulk drug substance frameworks, but quality control, sourcing, and testing rigor vary pharmacy to pharmacy in a way that doesn't apply to the single FDA-approved manufacturing process behind branded Egrifta SV. Ask any compounding pharmacy directly about their testing and licensing status.

How long does it take to see results after starting tesamorelin?

Phase 3 trials measuring visceral fat reduction and related outcomes like liver enzyme improvement generally ran over several months of daily dosing, not days or weeks. Individual response timelines vary, and your prescriber should set realistic expectations based on the specific outcome you're tracking (visceral fat, liver markers, or IGF-1 levels) rather than a single universal timeframe.

Can you get tesamorelin through a telehealth platform?

Many telehealth platforms do prescribe tesamorelin, most often for off-label use, following a virtual evaluation and bloodwork. This is a legitimate route as long as the platform employs licensed prescribers who actually review your history and labs rather than rubber-stamping requests. The prescription then gets filled through a licensed pharmacy, branded or compounded.

Sources

1. Nature Reviews Drug Discovery, 2011: Describes tesamorelin's mechanism as a GHRH analogue and its development as a drug
2. PubMed, Tesamorelin overview, 2012: Summarizes tesamorelin's pharmacology and clinical development
3. Annals of Pharmacotherapy, 2012: Reviews tesamorelin as a GHRH analogue approved for HIV-associated lipodystrophy
4. Journal of Clinical Endocrinology and Metabolism, 2010: Pooled analysis of two phase 3 double-blind placebo-controlled trials with safety extension data supporting the HIV lipodystrophy indication
5. AIDS, 2017: Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV
6. The Lancet HIV, 2019: Randomized double-blind multicenter trial of tesamorelin's effects on NAFLD in HIV
7. AIDS, 2021: Tesamorelin improves fat quality independent of changes in fat quantity
8. Journal of Clinical and Translational Science, 2023: Post hoc analysis of phase 3 trial comparing tesamorelin response with and without dorsocervical fat
9. AIDS, 2024: Efficacy and safety of tesamorelin in people with HIV on integrase inhibitor regimens
10. Journal of Infectious Diseases, 2025: Trial of tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity
11. Journal of Clinical Endocrinology and Metabolism, 2022: Describes clinical approach to diagnosing lipodystrophy syndromes
12. Annales d'Endocrinologie, 2012: Outlines diagnostic criteria for lipodystrophy syndrome
13. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026: Reviews therapeutic peptides in orthopaedics, including evidence gaps outside approved indications
14. American Journal of Sports Medicine, 2026: Primer for sports medicine physicians on injectable peptide therapy including GHRH analogues
15. Best Practice & Research Clinical Endocrinology & Metabolism, 2013: Reviews growth hormone axis effects and monitoring considerations in aging populations
16. 21 U.S.C. 353a, pharmacy compounding: Establishes the legal basis for 503A patient-specific pharmacy compounding
17. 21 CFR 216.24, the 503B Bulks List: Defines the bulk drug substances list applicable to 503B outsourcing facilities
18. 21 CFR 216.23, the final 503A Bulks List: Defines the bulk drug substances list applicable to 503A compounding
19. FDA, bulk drug substances used in compounding under section 503A: Explains FDA's framework for evaluating bulk drug substances used in 503A compounding
20. FDA, bulk drug substances nominated for use in compounding (current list): Lists bulk drug substances nominated for compounding use, which readers should check directly for tesamorelin's current status
21. Drugs@FDA, FDA-approved drug products database: Authoritative database to confirm Egrifta/Egrifta SV's FDA approval status and labeling
22. Clinical Pharmacokinetics, 2015: Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects supporting the daily dosing schedule
23. AIDS, 2011: Studies relationship between tesamorelin's effect on inflammatory markers and visceral fat reduction
24. Drug Testing and Analysis, 2021: Reviews advances in detection methods for GHRH synthetic analogs relevant to anti-doping testing
25. Sports Medicine (Auckland, N.Z.), 2026: Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, including doping considerations